About this source
- Kind
- Regulatory or official document
- Primary or secondary
- primary
- Peer review
- not peer reviewed
- Retraction status
- None known
- Date checked
- 14 November 2026
Limitations
A US regulator's press announcement, not UK law. It is a summary; the full prescribing information was not read. Applies to the United States only.
Cited in
US accelerated approval, Barth syndrome
Elamipretide · Research finding
FDA safety summary
Elamipretide · Safety finding
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.